Combination Immunotherapy for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a combination of four treatments on patients with advanced pancreatic cancer who did not respond to previous chemotherapy. The treatments include a drug to improve blood flow, two therapies to help the immune system fight cancer, and a vaccine to boost the immune response against cancer cells.
Who Is on the Research Team?
Katherine Bever, MD
Principal Investigator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institution
Are You a Good Fit for This Trial?
Adults over 18 with metastatic pancreatic cancer that's worsened after chemotherapy can join this trial. They must understand and agree to the study, have at least one measurable tumor, be in good physical condition (ECOG 0 or 1), use birth control, and have proper organ function. Exclusions include allergies to penicillin/sulfa, brain metastases, recent treatments or surgeries, uncontrolled illnesses, certain drug uses, severe hypersensitivities, significant heart disease or infections like HIV.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tadalafil, pembrolizumab, ipilimumab, and CRS-207
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CRS-207
- Ipilimumab
- Pembrolizumab
- Tadalafil
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Lustgarten Foundation
Collaborator